Valerie Odegard

Valerie Odegard

Company: Silverback Therapeutics

Job title: Chief Scientific Officer


Valerie Odegard, Ph.D., is the Chief Scientific Officer of Silverback Therapeutics. She has over 15 years of experience in immunotherapy drug development across multiple therapeutic areas.  Prior to Silverback, Dr. Odegard served as Vice President of R&D at Juno Therapeutics, where she was responsible for advancing novel cellular immunotherapies into clinical development.  Prior to Juno, she held research leadership positions at Novo Nordisk and Trubion Pharmaceuticals, where she oversaw the discovery and preclinical development of therapeutics for oncology and inflammatory conditions.  Dr. Odegard received her Ph.D. in Immunobiology from Yale University. 


Live Q&A 3:10 pm

Read more

day: Online Conference

Development of a Potent, Tumor Localized TLR8 Agonist 1:50 pm

• Tumors refractory to immunotherapies, such as T cell checkpoint blockade, as known to be replete with myeloid cells. • Clinical development of systemically administered myeloid cell agonists has been hindered by acute toxicities due to peripheral activation of these cell types • Development of a novel therapeutic comprised of a potent toll-like receptor (TLR)…Read more

day: Online Conference

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.